DeNIRO® & DeNIRO® 2.0 NIR Fluorometers. The first reliable, affordable and easy-to-use handheld point-of-care Near-Infrared Fluorometers.
Detact has developed a portable fluorometer sold under its proprietary trademark (US & EU) DeNIRO®. The DeNIRO® is unique, enabling fluorescence detection in the near-IR (700-1000 nm wavelength range).
Apart from assay development, Detact can develop the complete assay kit and point-of-care reader. In the past, Detact developed the DeNIRO®, the first commercially available handheld Near-Infrared Fluorometer. It allows specific point-of-care testing to work with the Detact Diagnostics assays/tests.
Detact is currently developing a 2.0 version that is smaller, cheaper to manufacture, yet connectable to cloud/telehealthcare systems.
Infrared minimises contaminants' effects in the sample and gives a high level of accuracy even with significantly diluted samples.
The patented Detact Diagnostics® VIPER® platform technology is based on the immediate release of a quenched Near-Infrared (NIR) molecule from its peptide bond after contact with a specific bacteria, viral or fungal enzyme, which emits NIR-light (NIRL), measured in Relative Fluorescent Units (RFU’s).
The DeNIRO® & DeNIRO® 2.0 accurately measure in this range and outperform all bench-top fluorometers in their functionality.
(The DeNIRO® (right) is for research use only)
Click the link to download a copy of the recently published paper (Portable Near-Infrared Fluorometer for a Liposomal Blood Lactate Assay) from ACS Pharmacology & Translational Science on how the DeNIRO was successfully used in a published research application.
- Fast and highly accurate quantitation of bacterial, viral, fungal, and enzymatic activity in less than 5 seconds.
- High levels of accuracy even with very dilute samples.
- Using Infrared minimises the effects of contaminants in the sample.
- Portable Fluorometer
- Detects Near-Infrared Fluorescence
- Designed for VIPER® assays
- A versatile sample port enables fluorescence from multiple sample types.
(DeNIRO® 2.0 is in development for clinical use)